Solitary extramedullary plasmacytoma of the bladder

a case report and literature.

Waseem Khaliq, Ikechukwu Uzoaru, Ronald P. Konchanin, Ronald A. Sapiente, James R. Egner

Research output: Contribution to journalArticle

Abstract

Plasmacytoma is a rare B-lymphocyte neoplastic disorder that usually presents as the generalized disease multiple myeloma. Less than 5% of the cases present as a solitary mass of monoclonal plasma cells in the bone or soft tissue. Although solitary extramedullary plasmacytoma (SEP) may arise in any organ, it rarely involves the urinary bladder. A 67-year-old male without a history of multiple myeloma presented with urinary frequency and nocturia; he was later diagnosed with SEP of the bladder. The patient was initially treated with a course of radiation therapy without symptomatic improvement; therefore a chemotherapy regimen consisting of lenalidomide and dexamethasone was subsequently given for six cycles. SEP usually carries a better prognosis and higher cure rate than solitary plasmacytoma of bone, as SEP is radiation sensitive. The role of adjuvant chemotherapy in the treatment of SEP that is resistant to radiation therapy is not clear, since most of the recommendations have been derived from the experience of head and neck SEP. The literature also lacks recommendations for choice of a chemotherapy regimen and surveillance of isolated bladder plasmacytoma. Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission.

Original languageEnglish (US)
Pages (from-to)832-835
Number of pages4
JournalOncology
Volume24
Issue number9
StatePublished - Aug 2010

Fingerprint

Plasmacytoma
Urinary Bladder
Multiple Myeloma
Dexamethasone
Radiotherapy
Radiation
Nocturia
Bone and Bones
Drug Therapy
Adjuvant Chemotherapy
Plasma Cells
B-Lymphocytes
Neck
Head

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Khaliq, W., Uzoaru, I., Konchanin, R. P., Sapiente, R. A., & Egner, J. R. (2010). Solitary extramedullary plasmacytoma of the bladder: a case report and literature. Oncology, 24(9), 832-835.

Solitary extramedullary plasmacytoma of the bladder : a case report and literature. / Khaliq, Waseem; Uzoaru, Ikechukwu; Konchanin, Ronald P.; Sapiente, Ronald A.; Egner, James R.

In: Oncology, Vol. 24, No. 9, 08.2010, p. 832-835.

Research output: Contribution to journalArticle

Khaliq, W, Uzoaru, I, Konchanin, RP, Sapiente, RA & Egner, JR 2010, 'Solitary extramedullary plasmacytoma of the bladder: a case report and literature.', Oncology, vol. 24, no. 9, pp. 832-835.
Khaliq W, Uzoaru I, Konchanin RP, Sapiente RA, Egner JR. Solitary extramedullary plasmacytoma of the bladder: a case report and literature. Oncology. 2010 Aug;24(9):832-835.
Khaliq, Waseem ; Uzoaru, Ikechukwu ; Konchanin, Ronald P. ; Sapiente, Ronald A. ; Egner, James R. / Solitary extramedullary plasmacytoma of the bladder : a case report and literature. In: Oncology. 2010 ; Vol. 24, No. 9. pp. 832-835.
@article{94008c533c35447fb1e763c32be14120,
title = "Solitary extramedullary plasmacytoma of the bladder: a case report and literature.",
abstract = "Plasmacytoma is a rare B-lymphocyte neoplastic disorder that usually presents as the generalized disease multiple myeloma. Less than 5{\%} of the cases present as a solitary mass of monoclonal plasma cells in the bone or soft tissue. Although solitary extramedullary plasmacytoma (SEP) may arise in any organ, it rarely involves the urinary bladder. A 67-year-old male without a history of multiple myeloma presented with urinary frequency and nocturia; he was later diagnosed with SEP of the bladder. The patient was initially treated with a course of radiation therapy without symptomatic improvement; therefore a chemotherapy regimen consisting of lenalidomide and dexamethasone was subsequently given for six cycles. SEP usually carries a better prognosis and higher cure rate than solitary plasmacytoma of bone, as SEP is radiation sensitive. The role of adjuvant chemotherapy in the treatment of SEP that is resistant to radiation therapy is not clear, since most of the recommendations have been derived from the experience of head and neck SEP. The literature also lacks recommendations for choice of a chemotherapy regimen and surveillance of isolated bladder plasmacytoma. Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission.",
author = "Waseem Khaliq and Ikechukwu Uzoaru and Konchanin, {Ronald P.} and Sapiente, {Ronald A.} and Egner, {James R.}",
year = "2010",
month = "8",
language = "English (US)",
volume = "24",
pages = "832--835",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "9",

}

TY - JOUR

T1 - Solitary extramedullary plasmacytoma of the bladder

T2 - a case report and literature.

AU - Khaliq, Waseem

AU - Uzoaru, Ikechukwu

AU - Konchanin, Ronald P.

AU - Sapiente, Ronald A.

AU - Egner, James R.

PY - 2010/8

Y1 - 2010/8

N2 - Plasmacytoma is a rare B-lymphocyte neoplastic disorder that usually presents as the generalized disease multiple myeloma. Less than 5% of the cases present as a solitary mass of monoclonal plasma cells in the bone or soft tissue. Although solitary extramedullary plasmacytoma (SEP) may arise in any organ, it rarely involves the urinary bladder. A 67-year-old male without a history of multiple myeloma presented with urinary frequency and nocturia; he was later diagnosed with SEP of the bladder. The patient was initially treated with a course of radiation therapy without symptomatic improvement; therefore a chemotherapy regimen consisting of lenalidomide and dexamethasone was subsequently given for six cycles. SEP usually carries a better prognosis and higher cure rate than solitary plasmacytoma of bone, as SEP is radiation sensitive. The role of adjuvant chemotherapy in the treatment of SEP that is resistant to radiation therapy is not clear, since most of the recommendations have been derived from the experience of head and neck SEP. The literature also lacks recommendations for choice of a chemotherapy regimen and surveillance of isolated bladder plasmacytoma. Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission.

AB - Plasmacytoma is a rare B-lymphocyte neoplastic disorder that usually presents as the generalized disease multiple myeloma. Less than 5% of the cases present as a solitary mass of monoclonal plasma cells in the bone or soft tissue. Although solitary extramedullary plasmacytoma (SEP) may arise in any organ, it rarely involves the urinary bladder. A 67-year-old male without a history of multiple myeloma presented with urinary frequency and nocturia; he was later diagnosed with SEP of the bladder. The patient was initially treated with a course of radiation therapy without symptomatic improvement; therefore a chemotherapy regimen consisting of lenalidomide and dexamethasone was subsequently given for six cycles. SEP usually carries a better prognosis and higher cure rate than solitary plasmacytoma of bone, as SEP is radiation sensitive. The role of adjuvant chemotherapy in the treatment of SEP that is resistant to radiation therapy is not clear, since most of the recommendations have been derived from the experience of head and neck SEP. The literature also lacks recommendations for choice of a chemotherapy regimen and surveillance of isolated bladder plasmacytoma. Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission.

UR - http://www.scopus.com/inward/record.url?scp=77957905667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957905667&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 832

EP - 835

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 9

ER -